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Background and Purpose: Recently, acute intracranial stenting (ICS) has gained more
interest as a potential bailout strategy for large vessel occlusions (LVO) that are refractory
to thrombectomy. However, there are currently no reports on ICS in patients with
moderately severe stroke discussing the question if implementing a permanent stent
is feasible and leads to improved recanalization after failed thrombectomy.
Methods: We analyzed a largemulticenter database of patients receiving ICS for anterior
circulation LVO after failed thrombectomy. Inclusion criteria were defined as: Moderately
severe stroke (National Institute Health Stroke Scale (NIHSS) ≤9 on admission), anterior
circulation LVO, acute ICS after failed stent retriever MT. Primary endpoint was the rate
of improved successful recanalization after ICS defined as a modified Thrombolysis
In cerebral Infarction (mTICI) score≥2b. Favorable neurological outcome was defined
as an early neurological improvement (ENI) of 4 points or reaching 0 with respect to
baseline NIHSS.
Results: Forty-one patients met the inclusion criteria. A median of 2 retrievals were
performed (IQR 1–4) prior decision-making for ICS. ICS led in 90.2% (37/41) of cases to
a final mTICI≥2b with significant improvement (p < 0.001) after the last retrieval attempt.
The median NIHSS decreased (p = 0.178) from 7 (IQR 3.5–8) on admission to 2.5 (IQR
0–8.25) at discharge. ENI was observed in 47.4% (18/38). sICH occurred in 4.8% (2/41).
Conclusion: ICS after failed thrombectomy appears to effectively improve recanalization
rates in patients with moderately severe strokes. Thus, ICS should be considered also
for patients with baseline NIHSS ≤9 if thrombectomy fails.
Keywords: failed thrombectomy, stroke, intracranial stenosis, stent, ICAD
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INTRODUCTION
Mechanical thrombectomy (MT) has become the standard of
care for acute ischemic stroke due to large vessel occlusions
(LVO). However, up to 29% of all mechanical thrombectomies
(MT) fail due to several conditions, such as intracranial
atherosclerotic disease (ICAD), calcified wall-adherent thrombi,
dissections, or other rare pathologies (1–3). Accordingly, the best
currently available evidence for the endovascular treatment of
ICAD is based on the SAMMPRIS and the VISSIT study (4, 5)
showing the superiority of best medical treatment over elective
intracranial stenting. Recently, acute intracranial stenting (ICS)
has been reported to be a highly promising bailout strategy
for theses frustrating thrombectomy cases with predictably poor
outcomes (6–11). Since these cases are still rare, past retrospective
studies mostly analyzed heterogeneous cohorts, including a wide
range of stroke severities (12).
It has been suggested that a low NIHSS (National Institute
Health Stroke Scale) score is a more frequent observation in
patients with acute occlusions of preexisting ICAD, presumably
based on adaptation of collaterals to the chronic low flow
conditions (13, 14). However, these patients arriving with
comparably low NIHSS scores could still have a poor prognosis
and high risk for stroke recurrence without sufficient therapy
(15, 16). Therefore, it might not be reasonable to base decision-
making for bailout strategies after failed thrombectomy on
patients’ initial NIHSS score only.
This study analyzes ICS for patients with moderately severe
anterior circulation LVO strokes (NIHSS score ≤ 9 upon
admission) to better estimate potential risks and benefits. We
hypothesize that in this patient subgroup, ICS is a feasible




We analyzed all patients with moderately severe stroke from a
large international ICS multicenter cohort (n = 4751) treated
between 01/2014 and 12/2018. ICS after failed thrombectomy
was performed in 210 cases with a relative frequency of 4.4
% (210/4751) in relation to all thrombectomies performed
within the study period. Inclusion criteria were: (1) Moderately
severe stroke (admission NIHSS ≤ 9), (2) anterior circulation
LVO (3) MT performed exclusively with stent retrievers (4)
acute intracranial stenting as a bailout strategy (Figure 1). The
study was approved by the local ethics committee (Chamber
of Physicians, Hamburg, Germany). Due to the retrospective
and anonymized study design, informed consent of the patients
was not required. Some data were part of previously published
cohorts (7, 11).
Abbreviations: ASPECTS, Alberta Stroke Program Early CT Score; ENI, Early
Neurological Improvement; LVO, Large Vessel Occlusion; MT, Mechanical
Thrombectomy; mTICI, Modified Thrombolysis In cerebral Infarction; NIHSS,
National Institute Health Stroke Scale; ICS, Intracranial Stenting; ICAD,
Intracranial Atherosclerotic Disease; IVT, Intravenous Thrombolysis; sICH,
symptomatic Intracerebral Hemorrhage.
FIGURE 1 | Flow chart of patient inclusion.
Baseline Characteristics
Available baseline characteristics were analyzed (Table 1).
Early ischemic changes were graded with the Alberta Stroke
Program Early CT Score (ASPECTS) on non-contrast computed
tomography. Experienced neurologists examined all patients
applying the NIHSS on admission and discharge. If eligible, all
patients received intravenous thrombolysis (IVT) prior to MT.
Intervention
In all cases MT performed with approved stent retriever devices
did not lead to sufficient recanalization or direct reocclusion after
thrombectomy occurred. Accordingly, the number of retrieval
attempts as well as the moment of decision-making for ICS and
declaring thrombectomy as failed was left to the interventionalist.
All types of stent retriever, the number of thrombectomy
maneuvers, as well as the stent design (balloon or self-expanding)
were evaluated. The recanalization result was evaluated with the
modified thrombolysis in cerebral infarction (mTICI) score.
Procedural and Functional Outcome
Primary endpoint was the rate of improved recanalization after
ICS assessed by the rate of successful recanalization defined
as mTICI≥2b. Neurological outcome was assessed by the rate
of early neurological improvement (ENI) defined as a decrease
in NIHSS at discharge from baseline of at least 4 points as
previously described (17) or reaching 0. The rate of favorable
functional outcome was assessed as mRS≤2 at 90 days. Due to the
retrospective approach, ENI data for 3 patients and 90 day mRS
data for 14 patients were missing. For safety assessment, cases
with symptomatic intracranial hemorrhage (sICH) according to
ECASS-II (18), mortality, and intervention related complications
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TABLE 1 | Overview of patients’ baseline characteristics.
Baseline characteristics Study cohort (n = 41)
Clinical and imaging
Age (years), median (IQR) 64 (48–73)
Sex (men) % (n) 70.7 (29/41)
ASPECTS, median (IQR) 8 (8–10)
NIHSS on admission, median (IQR) 7 (3.5–8)










Intravenous thrombolysis, % (n) 61 (25/41)
CT to groin-puncture (minutes), median (IQR) 104 (74.0–148)
Type of stent, % (n)
Self-expandable 100 (41/41)
were evaluated. Further, the antiplatelet therapy regimes were
recorded and analyzed.
Statistical Analysis
Continuous variables are displayed as mean with SD or median
with interquartile range. For categorical data, absolute, and
relative frequencies are displayed. Wilcoxon test was performed
to compare stroke severity on admission and discharge, as well
as recanalization status before and after stenting. P ≤ 0.05 were
considered significant. Analyses were performed using SPSS V.25
(IBM Corporation, Armonk, New York, USA).
RESULTS
Baseline Characteristics
19.5% (41/210) of all patients in the multicenter ICS database
met the required inclusions criteria. Median age was 64 years
(IQR 48.5–73.5) and 70.7% (29/41) were men. On admission
median ASPECTS was 8 (IQR 8–10) and median 7 (IQR 3.5–
8), whereas the median pre-stroke mRS was 0 (IQR 0–1). 39%
(16/41) of the patients received IVT prior to MT. Target vessels
for ICS were ICA in 36.6% (15/41), MCA M1 in 53.7% (22/41)
and MCA M2 in 9.8% (4/41). A self-expandable stent (Acclino
flex R©, Neuroform R©, Solitaire R©, Enterprise R©, Wingspan R©) was
utilized in all cases (100%, 41/41) for bailout ICS. Information
on periprocedural antithrombotic medication was available in
51.1% (21/41). In 14.3% (3/21) IV acetylsalicylic acid only
and in 85.7% (18/21) glycoprotein-IIb/IIIa-antagonists were
administered. Post-interventionally, all patients received dual
antiplatelet therapy for 3 months. Table 1 gives an overview of
patients’ baseline characteristics.
FIGURE 2 | Admission and discharge boxplots of National Institutes of health
stroke scale scores.
TABLE 2 | Overview of procedural results, neurological and functional outcome,
complications, and mortality.
Results All patients (n = 41)
Procedural
Passes of retriever, median (IQR) 2 (1–4)
Successful recanalization after last pass 43.9 (18/41)
(mTICI 2b/3), n (%)
Successful recanalization after ICS 90.2 (37/41)
(mTICI 2b/3), n (%)
Neurological improvement
NIHSS discharge, median (IQR) 2.5 (0–8.25)
ENI at discharge % (n) 47.4 (18/38)
Complication
sICH % (n) 4.8 (2/41)
Functional outcome
mRS ≤2 at 90 days % (n) 74.1 (20/27)
Mortality
At 90 days % (n) 2.7 (1/27)
Procedural and Functional Outcome
Amedian of 2MTmaneuvers were performed (IQR 1–4) prior to
ICS. After the finalMT attemptmTICI≥2b was achieved in 43.9%
(18/41). Acute ICS significantly increased (p < 0.001) the rate
of mTICI≥2b to 90.2% (37/41). The median NIHSS decreased
from 7 (IQR 3.5–8) on admission to 2.5 (IQR 0–8.25) at discharge
(Figure 2) without reaching statistical significance (p = 0.178).
ENI was observed in 47.4% (18/38) and sICH occurred in 4.8%
(2/41) of all patients. At 90 days the rate of mRS≤2 was 74.1%
(20/27; Table 2) and the mortality was 2.7% (1/27).
DISCUSSION
Recent retrospective case series have suggested reconsidering
ICS as a bailout strategy when MT fails to recanalize LVOs
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(11, 19). All these ICS studies report on typical thrombectomy
cohorts with a median admission NIHSS ranging from 14 to
19 (12). However, there are currently no reports on ICS after
failed thrombectomy for a homogenous group of less severe
stroke patients. Accordingly, we defined strokes with a baseline
NIHSS ≤ 9 on admission as moderately severe. This study
assesses a potential benefit of ICS after failed thrombectomy for
this subgroup.
Successful recanalization is a strong predictor for long-term
favorable functional outcome (mRS≤2) after MT (20). In cases
with ICAD, acute or prolonged reocclusion after MT is a
severe complication leading to poor outcomes (21). Even with
supposedly higher proportions of low NIHSS on admission in
patients with ICAD due to possibly better adapted collateral flow,
a sufficient and sustainable vessel recanalization seems crucial
to increase chances for long-term favorable outcomes and to
prevent stroke recurrence (14). Thus, it is an important finding in
our study that ICS increased the rate of successful recanalization
leading to 90% mTICI≥2b after failed MT attempts.
ENI was observed in 47% of the cohort with a median
NIHSS decrease of 4.5 points from admission to discharge. This
finding suggests a neurological benefit of ICS in our cohort,
however the prespecified level of statistical significance was
not reached most likely due to the underpowered sample size
of the study. Furthermore, the 90 days favorable functional
outcome (mRS≤2) was above average (74.1%, 20/27) of past
thrombectomy landmark studies (1). This finding highlights
both, the limitations of the retrospective study design with
missing follow-up data and the strength of the finding, showing
that even if poor outcome had been observed in all 14 missing
patients, the final rate of favorable outcome would still have been
comparably good with 49% of mRS≤2 (20/41).
The necessity of antiplatelet therapy after permanent stenting
has always been a major concern in endovascular stroke
treatment due to its increased risk for intracerebral bleeding
(22). Choosing ICS for patients presenting with low NIHSS
might be of even higher concern since the risk-benefit balance
is not comparable to a patient with a high baseline NIHSS
facing a high risk of poor outcome. In our study on ICS for
moderately severe stroke, 2/41 patients experienced sICH. This
result is comparable to those in the HERMES meta-analysis
with 4.4% and is unexpectedly low compared to the latest
acute ICS studies that reported on sICH rates ranging from 8
to 17% (1, 12). Antithrombotic medication was administered
periinterventionally in all our cases, some even in combination
with IVT. Even though detailed information were only available
in 50% of all patients, our finding is in line with the latest studies
observing the safety of stenting combined with antiplatelet
therapy in the setting of acute tandem occlusions (23, 24).
Even though we do not have data on stent patency in this
cases series due to missing follow-up imaging, Chang et al. (19)
previously observed that a favorable 90 day outcome (mRS≤2) is
significantly associated with stent patency. The median number
of retrieval attempts in our study was 2. Since all cases were
performed in tertiary stroke centers with expertise in all kinds
of neurointerventions, this finding is consistent with the latest
reports on risk-benefit ratio of additional retrieval attempts and
encourages to perform acute ICS after a maximum of three
thrombectomy maneuvers even in patients with moderately
severe strokes (20, 25).
LIMITATIONS
Our study has all limitations that come along with a retrospective
study design. Major limitations are the aforementioned missing
data on antithrombotic medication and follow-up outcome
at 90 days in 14 patients as well as a control group
treated with IVT only for comparison of clinical efficacy and
safety endpoints.
CONCLUSION
This study with its focus on moderately severe stroke is in line
with recently published articles that suggested the feasibility of
ICS as a bailout strategy after failed thrombectomy leading to
improved recanalization in the endovascular treatment of acute
ischemic stroke.
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